Aptevo Therapeutics PE Ratio 2014-2021 | APVO

Current and historical p/e ratio for Aptevo Therapeutics (APVO) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Aptevo Therapeutics PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Aptevo Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 14.99 0.00
2021-06-30 22.43 $-5.49 0.00
2021-03-31 30.52 $-5.84 0.00
2020-12-31 36.65 $-3.31 0.00
2020-09-30 7.60 $-3.31 0.00
2020-06-30 8.35 $-3.45 0.00
2020-03-31 3.70 $-5.55 0.00
2019-12-31 9.16 $-12.61 0.00
2019-09-30 8.24 $-12.61 0.00
2019-06-30 12.41 $-18.21 0.00
2019-03-31 12.60 $-22.13 0.00
2018-12-31 17.78 $-24.79 0.00
2018-09-30 71.12 $-24.79 0.00
2018-06-30 69.86 $7.56 9.24
2018-03-31 45.78 $8.26 5.54
2017-12-31 59.36 $10.36 5.73
2017-09-30 32.06 $0.00 0.00
2017-06-30 28.98 $-74.23 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.004B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00